Helicobacter pylori (H. pylori) infection affects over 50% of the global population and is a major cause of gastritis, peptic ulcers, and gastric cancer. Current antibiotic regimens face challenges such as antibiotic resistance and adverse effects. Natural products provide a promising alternative, but their efficacy must be scientifically validated before clinical use. To address this need, we have developed an in vitro platform to evaluate anti-H. pylori properties of botanical extracts in a robust and reproducible manner.
The model comprises two components: 1) Direct antimicrobial activity determined by minimum inhibitory and bactericidal concentrations; 2) Anti-infective effects against live H. pylori infection of gastric epithelial cells. Using this platform, we have evaluated the anti-H. pylori properties of Boesenbergia rotunda (fingerroot) extracts. This provides evidence for the traditional use of fingerroot and validates it as an herbal medicine candidate. Our in vitro infection model allows rapid screening of natural product libraries to discover novel anti-H. pylori phytotherapies. It offers a standardized method as a part of a preclinical evaluation of safety and efficacy prior to human trials. This platform could be utilized by nutraceutical or pharmaceutical companies interested in scientifically developing new botanical therapies for H. pylori infection and gastritis. It addresses the need for evidence-based natural medicines to combat antibiotic resistance and improve treatment options against a global infection.
Besides uncovering novel targets for traditional medicine, the technology owner is able to provide screening, extraction, compound analysis and validation tests for natural compounds at the facilities.
This technology consists of an in vitro infection model using the human gastric epithelial cell line AGS to evaluate anti-Helicobacter activity of natural extracts.
This provides a robust and reproducible platform to quantify the anti-Helicobacter efficacy of natural extracts in a physiologically relevant gastric cell model.
Ideal partners for collaboration and value chain integration include:
The global market for Helicobacter pylori infection treatment is poised for robust growth, expected to reach US$ 1.26 billion by 2033 as per Future Market Insights. Rising prevalence coupled with antibiotic resistance drives demand for novel therapies. The technology provides a reliable in-house in vitro screening platform for the development of scientifically validated phytotherapies and functional foods. Standardized validation will enable rapid translation into premium nutraceuticals and therapeutics for the underserved natural medicine segment. As H. pylori prevalence is higher in developing countries, a large market would be seeking cost-effective, efficacious and natural solutions. This presents a timely opportunity to license a cost-effective screening technology with applications across pharmaceuticals, supplements, and food. Our platform accelerates R&D and commercialization of alternative therapies to combat a growing global infection.
The current state-of-the-art for anti-H. pylori drug discovery relies on conventional antimicrobial screening models that do not replicate human gastric physiology. This leads to poor translation from in vitro efficacy to clinical outcomes. Our approach provides a physiologically relevant infection model using human gastric cells that enables better predicting efficacy. The standardized and robust platform allows for a high throughput screening unmatched by current animal models in scale and cost. By accommodating natural product libraries, synthetic compounds, and combinations, it can unlock novel therapies beyond conventional antibiotics. The model helps to scientifically validate traditional medicines to meet regulatory and consumer demand for evidence-based natural options. With applications across pharmaceutical, nutraceutical, and food sectors, this versatile screening platform has the potential to outperform current state-of-the-art in replicating human gastritis pathology.